• Federal jury finds Guardant Health, GH (NASDAQ), willfully infringes University of Washington duplex sequencing patents exclusively licensed to TwinStrand Biosciences, Inc. and awards $ 83.4M in damages.
• Jury finds FDA-approved product Guardant 360® CDx infringes the University of Washington’s patents, along with all of Guardant Health’s commercial products which analyze cell free DNA obtained from blood draws to detect, screen, and/or characterize cancer.
• Guardant Health did not challenge the validity of the patents in district court.
• Previously, on October 10, 2023, the Patent Trial and Appeal Board rejected all of Guardant’ Health’s invalidity arguments regarding 30 claims of UW’s ‘127 patent.
• The duplex sequencing technology that is covered by these patents can deliver 10,000x greater accuracy than standard next generation sequencing, allowing for exquisitely sensitive mutation and genetic allele detection to inform critical medical decisions and drug development pipelines.

SEATTLE, Nov. 15, 2023 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from residual cancer detection to genetic toxicology, announced a successful jury verdict in the federal patent infringement case it brought with the University of Washington against Guardant Health. The jury found that Guardant Health willfully infringed two of the University of Washington’s duplex sequencing patents in the sale of its FDA-approved Guardant 360 CDx product, as well as all of its commercial products in cancer screening, detection, and characterization. The patents at issue were U.S. Patent No. 10,760,127 and U.S. Patent No. 10,287,631, both owned by the University of Washington and exclusively licensed to TwinStrand Biosciences, Inc., which was founded by the inventors of the patents. 

Read full article on prnewswire.com